

2 61294035797US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressed service."

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

X.Stantin

7. Stantin

Customer No.:

07278
PATENT TRADEMARK OFFICE

Docket No: 7238/0J504

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of:

Leendert KOENDERMAN, et al.

FEB 2 0 2003

Serial No.: 09/869,208

Art Unit:

1644

TECH CENTER 1600/2900

Confirmation No.: 9804

Filed: 15/12/01

Examiner:

Michail A BELYAVSKYI

For: DETECTION OF PREACTIVATED PHAGOCYTES

EXAMINER'S COURTESY COPY OF PENDING CLAIMS

Hon. Commissioner of Patents and Trademarks Washington, DC 20231 February 12, 2003

1. (Once amended) Antigen of a phagocyte, wherein the antigen may be recognized by at least one bacteriophage as can be isolated from the strains having accession numbers CBS 101481 and 101482.

2. (Once amended) Phagocyte-recognizing agent, wherein the

phagocyte-recognizing agent recognizes the antigen that is recognized by at least

one bacteriophage as can be isolated from the strains having accession numbers

CBS 101481 and 101482.

3. (Once amended) Phagocyte-recognizing agent according to

claim 2, wherein it possesses a group having a phagocyte-deactivating activity.

4. Pharmaceutical composition comprising a phagocyte-recognizing

agent capable of recognizing the antigen that is recognized by at least one

bacteriophage as can be isolated from the strains having accession numbers CBS

101481 and 101482 together with a pharmaceutically acceptable excipient or

carrier.

5. (Once amended) Method of detecting a preactivated phagocyte,

Wherein a phagocyte-recognizing agent capable of recognizing the antigen that is

recognized by at least one bacteriophage as can be isolated from the strains having

accession numbers CBS 101481 and 101482 is contacted with a phagocyte, and a

complex formed between the phagocyte-recognizing agent and the phagocyte is

detected.

{M:\7238\0j504\AL2497.DOC;1} Serial No. 09/869,208 Examiner's Courtesy Copy of Pending Claims

Docket No. 7238/0J504

6. (Once amended) Method according to claim 5, wherein the

agent is capable of competing with at least one bacteriophage as can be isolated

from the strains having accession numbers CBS 101481 and 101482, and a

complex between the phagocyte-recognizing agent and the phagocyte is detected.

7. (Once amended) Method according to claim 6, wherein the

agent is a bacteriophage.

8. (Once amended) Method according to claim 6, wherein the

agent is a fluorescent agent.

9. (Once amended) Method according to claim 8, wherein the

agent comprises Green or Blue Fluorescent Protein.

10. (Once amended) Method according to claim 8, wherein

detection is performed by means of a Fluorescence-Activated Cell Sorter (FACS).

11. (Once amended) Method according to claim 5, wherein the

detection is performed by means of an ELISA.

{M:\7238\0j504\AL2497.DOC;1} Serial No. 09/869,208 Examiner's Courtesy Copy of Pending Claims

Docket No. 7238/0J504

12. (Once amended) Method according to claim 5, wherein the phagocyte is derived from a person of which it is thought that it suffers from an affection chosen from the group consisting of i) organ-bound inflammatory diseases; ii) septic shock; iii) allergies; and iv) auto-immune diseases; or of a person

having undergone a transplantation.

13. (Once amended) Method according to claim 12, wherein for detection blood from a person is lysed using an isotonic, cold NH₄CI-solution yielding a phagocyte-containing solution.

{M:\7238\0j504\AL2497.DOC;1} Serial No. 09/869,208 Examiner's Courtesy Copy of Pending Claims